Tag: cardiovascular events
-
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz "ORAL Surveillance" Trial Which Started in 2014 (Posted by Tom Lamb at Drug Injury Watch) One year ago Pfizer released some preliminary…
-
Drug Safety Issue for Stelara: Severe Cardiovascular Events Soon After Initiation of Stelara Treatment
Stelara-Associated Acute Coronary Syndrome, Stroke, and Unstable Angina Seen in Recent Stelara French Medical Study (Posted by Tom Lamb at DrugInjuryWatch.com) Stelara (ustekinumab) was approved by the FDA in 2009, initially for…
-
Lemtrada Cardiovascular Reactions Can Occur Within 1-3 Days Of Infusions In People Without Any Identifiable Risk Factors
Unpredictable And Potentially Fatal Immune-Mediated Reactions Can Occur Within Months And Up To At Least 4 Years After Lemtrada Treatments (Posted by Tom Lamb at DrugInjuryWatch.com) The UK Medicines and Healthcare Products…
-
Lemtrada: Reports Of Serious Cardiovascular Events And Immune-Mediated Reactions Under Investigation
UK Drug Safety Regulator MHRA Imposes Lemtrada Use Restrictions And Mandates Patient Monitoring For Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2019 the UK's Medicines and Healthcare products Regulatory…
-
Cardiovascular Safety Issues For Onglyza And Kombiglyze Will Be Discussed At April 2015 FDA Advisory Committee Meeting
These Two New AstraZeneca Diabetes Medications With Saxagliptin Are Part Of The Incretin Mimetic Class Of Drugs (Posted by Tom Lamb at DrugInjuryWatch.com)At an April 14, 2015 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, results of the…
-
Increasingly Popular Testosterone Replacement Therapy Drugs Are Linked To Myocardial Infarctions Or Heart Attacks, Strokes, And Deaths
Medical Studies Show An Increased Risk Of Cardiovascular Events In Older Men Prescribed Testosterone Medications Such As Axiron, AndroGel, And Testim (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "FDA evaluating risk of stroke, heart…